Grant: Proof of Principle Program - Phase II
McGill University
$122,670.00
A Novel Regenerative Drug Therapy to Restore Natural Insulin Secretion in Diabetes Mellitus
EF 2012-13
Résumé
INGAP Peptide (Exsulin) is a first-in-class pancreatic islet regeneration agent that regrows insulin-producing cells in the diabetic pancreas. The lead peptide candidate is currently in Phase 2 development for treatment of insulin-dependent diabetes. Regeneration of pancreatic islets restores the metabolic hormones responsible for normal physiologic glycemic control and promotes a return of natural insulin production, can lower HbA1c with fewer hypoglycemic events, and decrease the chronic and life-threatening complications of diabetes, thus representing a significant breakthrough in diabetes management. In the proposed study, new and more potent analogues of INGAP peptide will be developed to enhance its activity in patients with diabetes.
Programme
Proof of Principle Program - Phase II
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
268561
Name
Rosenberg Lawrence
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Kinexum Metabolics Canada, Inc. (Montreal, QC); Kinexum Metabolics Canada, Inc. (Montreal, QC)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
A Novel Regenerative Drug Therapy to Restore Natural Insulin Secretion in Diabetes Mellitus
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$122,670
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase II
Keyworddelim
Diabetes Melitus; Drug Discovery; Ingap Analogues; Ingap-Islet Neogenesis Associated Protein; Islet Neogenesis
Abstract
INGAP Peptide (Exsulin) is a first-in-class pancreatic islet regeneration agent that regrows insulin-producing cells in the diabetic pancreas. The lead peptide candidate is currently in Phase 2 development for treatment of insulin-dependent diabetes. Regeneration of pancreatic islets restores the metabolic hormones responsible for normal physiologic glycemic control and promotes a return of natural insulin production, can lower HbA1c with fewer hypoglycemic events, and decrease the chronic and life-threatening complications of diabetes, thus representing a significant breakthrough in diabetes management. In the proposed study, new and more potent analogues of INGAP peptide will be developed to enhance its activity in patients with diabetes.
Competitiondate
201209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rosenberg, Lawrence
Approvedterm
1 an 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $122,670~ $0~